%0 Journal Article
%T Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study
%A Fushimi
%A Yoshiro
%A Hirukawa
%A Hidenori
%A Horiya
%A Megumi
%A Iwamoto
%A Yuichiro
%A Kaku
%A Kohei
%A Kan
%A Yuki
%A Kaneto
%A Hideaki
%A Kinoshita
%A Tomoe
%A Kohara
%A Kenji
%A Mashiko
%A Akiko
%A Mizoguchi-Tomita
%A Akiko
%A Mune
%A Tomoatsu
%A Nakanishi
%A Shuhei
%A Nishioka
%A Momoyo
%A Obata
%A Atsushi
%A Okauchi
%A Seizo
%A Sanada
%A Junpei
%A Shimoda
%A Masashi
%A Tatsumi
%A Fuminori
%J -
%D 2020
%R https://doi.org/10.1155/2020/4861681
%X Recently, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been very often used in subjects with type 2 diabetes mellitus (T2DM). In addition, combination drugs of both inhibitors have attracted much attention in aspects of its cost-effectiveness and improvement of patients¡¯ adherence. However, it is still poorly understood which factors are related to the efficacy of SGLT2 inhibitors as add-on therapy to DPP-4 inhibitors. Therefore, we aimed to elucidate in which type of individuals and/or under which conditions canagliflozin as add-on therapy to teneligliptin could exert more beneficial effects on glycemic control and/or renal protection. We retrospectively analyzed 56 Japanese subjects with T2DM in the real-world clinical practice. Three months after starting the combination therapy, the change of HbA1c (¦¤HbA1c) was strongly related to HbA1c levels at baseline. As expected, serum glucagon level was increased after starting the combination therapy. Interestingly, however, the change of glucagon levels (¦¤glucagon) was not related to HbA1c levels at baseline, ¦¤HbA1c, and other parameters, which indicated that the increase of glucagon did not clinically affect the effectiveness of combination therapy. In addition, the change of urinary albumin excretion (¦¤UAE) was negatively correlated with systolic blood pressure and HbA1c levels at baseline and positively correlated with the change of systolic blood pressure (¦¤sBP) in univariate analysis. Furthermore, in multivariate analysis, only ¦¤sBP was the independent factor associated with ¦¤UAE. Taken together, canagliflozin as add-on therapy to teneligliptin improves glycemic control in a ¦¤glucagon-independent manner and reduces UAE in a ¦¤sBP-dependent manner in Japanese subjects with T2DM
%U https://www.hindawi.com/journals/jdr/2020/4861681/